Genmab Statistics
Want to see GMAB full AI Analyst Report?
Genmab (GMAB) Stock Statistics & Valuation Metrics
Total Valuation
Genmab has a market cap or net worth of $31.11B. The enterprise value is $25.60B.
- Market Cap
- $31.11B
- Enterprise Value
- $25.60B
Share Statistics
Genmab has 624,058,530 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 624,058,530
- Owned by Insiders
- ―
- Owned by Institutions
- 4.19%
Financial Efficiency
Genmab’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 8.54%.
- Return on Equity (ROE)
- 0.17
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 8.54%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- 1.15M
- Profits Per Employee
- 297.09K
- Employee Count
- 3,244
- Asset Turnover
- 0.29
- Inventory Turnover
- 17.22
Valuation Ratios
The current PE Ratio of Genmab is 42.80. Genmab’s PEG ratio is -0.51.
- PE Ratio
- 42.80
- PS Ratio
- 7.27
- PB Ratio
- 4.92
- Price to FCF
- 37.00
- Price to Operating Cash Flow
- 35.53
- PEG Ratio
- -0.51
Income Statement
In the last 12 months, Genmab had revenue of 3.72B and earned 963.76M in profits. Earnings per share was 1.55.
- Revenue
- 3.72B
- Gross Profit
- 3.41B
- Operating Income
- 1.25B
- Pretax Income
- 1.20B
- Net Income
- 963.76M
- EBITDA
- 1.34B
- Earnings Per Share (EPS)
- 1.55
Cash Flow
In the last 12 months, operating cash flow was 874.35M and capital expenditures -32.00M, giving a free cash flow of 842.34M billion.
- Operating Cash Flow
- 874.35M
- Free Cash Flow
- 842.34M
- Free Cash Flow per Share
- 1.38
Dividends & Yields
Genmab pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.70%
- Earnings Yield
- 2.34%
Stock Price Statistics
- Beta
- 0.70
- 52-Week Price Change
- 69.87%
- 50-Day Moving Average
- 40.80
- 200-Day Moving Average
- 31.39
- Relative Strength Index (RSI)
- 59.07
- Average Volume (3m)
- 4.21M
Important Dates
Genmab upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- ―
Financial Position
Genmab as a current ratio of 2.02, with Debt / Equity ratio of 93.01%
- Current Ratio
- 2.02
- Quick Ratio
- 2.01
- Debt to Market Cap
- 0.28
- Net Debt to EBITDA
- 2.78
- Interest Coverage Ratio
- 20.49
Taxes
In the past 12 months, Genmab has paid 241.19M in taxes.
- Income Tax
- 241.19M
- Effective Tax Rate
- 0.20
Enterprise Valuation
Genmab EV to EBITDA ratio is 25.03, with an EV/FCF ratio of 40.95.
- EV to Sales
- 8.04
- EV to EBITDA
- 25.03
- EV to Free Cash Flow
- 40.95
- EV to Operating Cash Flow
- 39.45
Balance Sheet
Genmab has $1.86B in cash and marketable securities with $5.20B in debt, giving a net cash position of -$3.34B billion.
- Cash & Marketable Securities
- $1.86B
- Total Debt
- $5.20B
- Net Cash
- -$3.34B
- Net Cash Per Share
- -$5.35
- Tangible Book Value Per Share
- -$4.67
Margins
Gross margin is 92.60%, with operating margin of 30.53%, and net profit margin of 16.95%.
- Gross Margin
- 92.60%
- Operating Margin
- 30.53%
- Pretax Margin
- 18.09%
- Net Profit Margin
- 16.95%
- EBITDA Margin
- 32.13%
- EBIT Margin
- 31.05%
Analyst Forecast
The average price target for Genmab is $64.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $64.57
- Price Target Upside
- 25.70% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 9
- Revenue Growth Forecast
- 19.61%
- EPS Growth Forecast
- -50.40%
Scores
- Smart Score
- 9
- AI Score
- 63
